Look at our new launches, GSK urges, as its respiratory woes steal the limelight

GlaxoSmithKline is as upbeat as ever about the key launches it has underway—including its new shingles vaccine Shingrix—but take a look at the business as a whole, and you'll find sore spots.

None so sore as the company's crucial respiratory franchise, but its HIV business isn't pain-free either, analysts pointed out Wednesday after the company released first-quarter earnings.